Bpifrance

Co-created in July 2016 by Justine LIPUMA, PhD in microbiology, and Christine PONCET-DOISE, Senior Research Engineer at INRA, MYCOPHYTO is the result of 30 years of experimentation in biological crop protection.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Lisaqua is developing a unique aquaculture process to raise prawns without antibiotics and without polluting waste

Starkage Therapeutics is a discovery-stage biotechnology company. They also provide treatment for idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibroses.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.

Lisaqua is developing a unique aquaculture process to raise prawns without antibiotics and without polluting waste

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Seekyo is a privately-owned biotech company that develops the next generation of chemotherapies By targeting the microenvironment of solid tumors while sparing healthy tissues, our aim is to provide treatments without adverse effects to cancer patients. Seekyo’s Smart Drugs transport potent anticancer agents in an innocuous manner toward safe tissues, provide efficient recognition of malignant specificities thanks to its targeting unit and allow the controlled release of the parent drug exclusively at the tumour site, based on its versatile enzyme-responsive self-immolative linker.

OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Honing Biosciences SAS is a bio-therapeutics company based in Paris, France, specializing in the development and enhancement of cell-based therapies for cancer and other chronic diseases. The company utilizes its proprietary molecular CellTune technology to create tunable cell therapeutics that enable precise control over the dynamic delivery of proteins in patients. This innovation allows for the regulation of protein expression at the cell surface and the secretion of therapeutic agents such as enzymes, cytokines, and antibodies, which can be adapted based on the clinical progression of a patient's condition. Honing Biosciences also offers therapies like CAR-T cell therapy and checkpoint inhibitors, which aim to improve treatment efficacy while minimizing adverse effects associated with earlier therapeutic generations. Established in 2018, the company focuses on advancing immunotherapy and reconstituting cell therapies to better engage the body’s immune system in combating diseases.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.